1. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial
- Author
-
Verheij, Floris S, Omer, Dana M, Williams, Hannah, Lin, Sabrina T, Qin, Li-Xuan, Buckley, James T, Thompson, Hannah M, Yuval, Jonathan B, Kim, Jin K, Dunne, Richard F, Marcet, Jorge, Cataldo, Peter, Polite, Blase, Herzig, Daniel O, Liska, David, Oommen, Samuel, Friel, Charles M, Ternent, Charles, Coveler, Andrew L, Hunt, Steven, Gregory, Anita, Varma, Madhulika G, Bello, Brian L, Carmichael, Joseph C, Krauss, John, Gleisner, Ana, Guillem, José G, Temple, Larissa, Goodman, Karyn A, Segal, Neil H, Cercek, Andrea, Yaeger, Rona, Nash, Garrett M, Widmar, Maria, Wei, Iris H, Pappou, Emmanouil P, Weiser, Martin R, Paty, Philip B, Smith, J Joshua, Wu, Abraham J, Gollub, Marc J, Saltz, Leonard B, and Garcia-Aguilar, Julio
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Rare Diseases ,Radiation Oncology ,Clinical Trials and Supportive Activities ,Clinical Research ,Orphan Drug ,Patient Safety ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Humans ,Adenocarcinoma ,Chemoradiotherapy ,Neoadjuvant Therapy ,Neoplasm Recurrence ,Local ,Neoplasm Staging ,Organ Preservation ,Rectal Neoplasms ,Treatment Outcome ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.To assess long-term risk of local tumor regrowth, we report updated organ preservation rate and oncologic outcomes of the OPRA trial (ClinicalTrials.gov identifier: NCT02008656). Patients with stage II/III rectal cancer were randomly assigned to receive induction chemotherapy followed by chemoradiation (INCT-CRT) or chemoradiation followed by consolidation chemotherapy (CRT-CNCT). Patients who achieved a complete or near-complete response after finishing treatment were offered watch-and-wait (WW). Total mesorectal excision (TME) was recommended for those who achieved an incomplete response. The primary end point was disease-free survival (DFS). The secondary end point was TME-free survival. In total, 324 patients were randomly assigned (INCT-CRT, n = 158; CRT-CNCT, n = 166). Median follow-up was 5.1 years. The 5-year DFS rates were 71% (95% CI, 64 to 79) and 69% (95% CI, 62 to 77) for INCT-CRT and CRT-CNCT, respectively (P = .68). TME-free survival was 39% (95% CI, 32 to 48) in the INCT-CRT group and 54% (95% CI, 46 to 62) in the CRT-CNCT group (P = .012). Of 81 patients with regrowth, 94% occurred within 2 years and 99% occurred within 3 years. DFS was similar for patients who underwent TME after restaging (64% [95% CI, 53 to 78]) and patients in WW who underwent TME after regrowth (64% [95% CI, 53 to 78]; P = .94). Updated analysis continues to show long-term organ preservation in half of the patients with rectal cancer treated with total neoadjuvant therapy. In patients who enter WW, most cases of tumor regrowth occur in the first 2 years.
- Published
- 2024